View Older Stories View More Recent Stories

May 13, 2025 04:08PM Exelixis (EXEL) Tops Q1 EPS by 25c, provides guidance
Apr 17, 2025 04:32AM Citizens JMP Reiterates Market Outperform Rating on Exelixis (EXEL)
Apr 12, 2025 04:00AM Biotech sector Q1 earnings preview from RBC Capital Markets
Apr 9, 2025 07:22AM Guggenheim Reiterates Buy Rating on Exelixis (EXEL)
Mar 27, 2025 06:37AM H.C. Wainwright Reiterates Buy Rating on Exelixis (EXEL)
Mar 26, 2025 01:08PM Stifel Reiterates Hold Rating on Exelixis (EXEL)
Mar 26, 2025 01:07PM Exelixis (EXEL) PT Raised to $33 at Leerink Partners
Mar 26, 2025 10:56AM Citi Reiterates Buy Rating on Exelixis (EXEL)
Mar 26, 2025 09:15AM Exelixis (EXEL) Announces U.S. FDA Approval of CABOMETYX
Feb 12, 2025 07:53AM Exelixis (EXEL) PT Raised to $36 at Stifel
Feb 12, 2025 04:18AM JMP Securities Reiterates Market Outperform Rating on Exelixis (EXEL)
Feb 11, 2025 04:12PM Exelixis (EXEL) Tops Q4 EPS by 16c, provides guidance
Feb 3, 2025 04:43AM JMP Securities Biotechnology Overview
Jan 27, 2025 09:34AM Stifel Reiterates Hold Rating on Exelixis (EXEL)
Jan 27, 2025 09:20AM Exelixis (EXEL) PT Raised to $43 at Truist on 'Increased Confidence In Zanza'
Jan 27, 2025 07:13AM H.C. Wainwright Reiterates Buy Rating on Exelixis (EXEL)
Jan 27, 2025 04:44AM JMP Securities Reiterates Market Outperform Rating on Exelixis (EXEL)
Jan 27, 2025 04:14AM Morgan Stanley Upgrades Exelixis (EXEL) to Overweight
Jan 24, 2025 02:31PM Exelixis (EXEL) Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study
Jan 23, 2025 04:11PM Oppenheimer Downgrades Exelixis (EXEL) to Perform
Jan 23, 2025 07:17AM JMP Securities Reiterates Market Outperform Rating on Exelixis (EXEL)
Jan 15, 2025 05:11PM Exelixis (EXEL) PT Raised to $41 at Oppenheimer
Jan 15, 2025 08:34AM Exelixis (EXEL) PT Raised to $42 as Truist Securities Sees Shares Gain Potential
Jan 13, 2025 12:50PM RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
Jan 7, 2025 07:52AM Exelixis (EXEL) PT Raised to $42 at Guggenheim
Dec 26, 2024 05:12AM Brookline Capital Markets Starts Exelixis (EXEL) at Buy
Dec 23, 2024 05:25AM Brookline Capital Markets Starts Exelixis (EXEL) at Buy
Dec 19, 2024 04:10PM BMO Capital Downgrades Exelixis (EXEL) to Market Perform
Dec 19, 2024 11:16AM RBC Capital's Game Changers: 'Disruptive Forces in Biotech'
Dec 17, 2024 06:13AM BofA Securities Downgrades Exelixis (EXEL) to Neutral
Nov 27, 2024 07:08AM Stephens Reiterates Equal Weight Rating on Exelixis (EXEL)
Oct 30, 2024 08:42AM Exelixis (EXEL) PT Raised to $36 at BMO Capital
Oct 30, 2024 07:46AM Exelixis (EXEL) PT Raised to $36 at Piper Sandler
Oct 30, 2024 06:27AM Exelixis (EXEL) PT Raised to $29 at Stephens
Oct 30, 2024 05:47AM Exelixis (EXEL) PT Raised to $38 at Citi
Oct 29, 2024 04:09PM Exelixis (EXEL) Tops Q3 EPS by 13c, Tops on Revenue; Offers FY24 Revenue Guidance
Oct 21, 2024 08:40AM Exelixis (EXEL) PT Raised to $34 at TD Cowen
Oct 16, 2024 06:54AM Leerink Partners Reiterates Market Perform Rating on Exelixis (EXEL)
Oct 16, 2024 06:50AM Exelixis (EXEL) PT Raised to $34 at RBC Capital
Oct 16, 2024 06:03AM Goldman Sachs Reiterates Sell Rating on Exelixis (EXEL)
Oct 15, 2024 02:54PM TD Cowen Reiterates Buy Rating on Exelixis (EXEL)
Oct 15, 2024 02:32PM BMO Capital on Exelixis (EXEL): 'we do not expect a cabo generic entry by MSN until at least the latest...'
Oct 15, 2024 02:14PM Morgan Stanley Out Mixed on Exelixis (EXEL), PT Raised to $30, 'ruling is short of a home run scenario'
Oct 15, 2024 01:57PM Exelixis (EXEL) Announces Update on Second Patent Litigation Trial with MSN Laboratories
Oct 15, 2024 11:29AM Exelixis (EXEL) Strength Tied to US Court Ruling in Patent Case vs MSN
Oct 14, 2024 02:33PM Truist Securities Reiterates Buy Rating on Exelixis (EXEL)
Oct 14, 2024 10:57AM Citi Reiterates Buy Rating on Exelixis (EXEL)
Oct 14, 2024 10:57AM Stephens Reiterates Equal Weight Rating on Exelixis (EXEL)
Oct 14, 2024 08:02AM Exelixis (EXEL) and Merck (MRK) Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA
Sep 19, 2024 02:46AM UBS Starts Exelixis (EXEL) at Neutral
View More Recent Stories View Older Stories